$300 million invested in vaccine innovations to end Covid-19 and prevent future epidemics

Wellcome and the Bill & Melinda Gates Foundation have both pledged $150 million each to the Coalition for Epidemic Preparedness Innovations (CEPI) to help end the Covid-19 pandemic and prevent another major outbreak.

In Peru, a healthcare worker wearing PPE administers a Covid-19 vaccine to an older man wearing a mask and visor.

Vilca / UNICEF

Listen to this article
$300 million invested in vaccine innovations to end Covid-19 and prevent future epidemics
Elapsed time:00:00Total time:00:00

To end the Covid-19 pandemic we need to be one step ahead of its variants. This means improving existing vaccines and making them easily accessible to everyone that needs them.

The threat of another major pandemic also remains high. Since 1980, the number of disease outbreaks has more than tripled.

That’s why Wellcome and the Bill & Melinda Gates Foundation are committing a further $150 million each to help protect lives against emerging infectious diseases.

The funding commitment comes ahead of a global conference in March 2022 where CEPI is seeking $3.5 billion to support its ongoing work.

Invest early to prevent worst case scenarios 

Historically, investment to prevent epidemics has followed cycles of 'panic and neglect'.

Vital tools, vaccines and treatments rarely get developed when there are few cases of an infectious disease. Yet when there is a crisis, the world is left to scramble to find solutions. People die as a result, and outbreaks become epidemics or even pandemics.

Wellcome founded CEPI in 2017 with partners from Norway, Germany, Japan, India and the Bill & Melinda Gates Foundation to address this. By working in a coalition with vaccine developers, manufacturers, governments, philanthropies, civil society, and global health, CEPI can find solutions to some of the world’s most dangerous diseases when the market cannot.

So far it has invested in:

  • 21 vaccine candidates against Lassa, MERS, Rift Valley Fever, Nipah and Chikungunya.
  • 3 different vaccines platforms so scientists can quickly develop a vaccine against a new unknown virus when it emerges.
  • 14 Covid-19 vaccine candidates – including the Oxford/AstraZeneca and Novavax vaccines.
  • Research and development necessary to enable these innovations.

At the heart of its work, CEPI makes sure the tools it creates are accessible to everyone who needs them, wherever they are. By focusing on the needs of low- and middle-income countries throughout its vaccine development approaches, it can address issues like supply and thermostability early on.

Ultimately, it aims to develop lifesaving vaccines against any new, unknown disease within 100 days of the pathogen being sequenced.

Global solutions need collective investment 

Covid-19, Ebola and SARS are just a few recent examples of deadly outbreaks that have escalated. There are many more examples throughout history.

Habitat destruction, the climate crisis, intensive farming and international travel all mean that when a new disease emerges its likely to spread across the world faster than ever before.

The only way to ensure there are tools to stop an outbreak from becoming a major pandemic is by continuing to fund research and development at scale.

This will only happen if world leaders learn lessons from previous crises.

CEPI recently launched its $3.5 billion, five-year plan to dramatically reduce the risks of pandemics and epidemics.

“Our new commitment of $150m recognises the enormous potential CEPI has to protect lives against emerging infectious diseases. The effects of Covid-19 have been sobering.

“We urge leaders to provide their support and ensure CEPI reaches their funding target. It is in the world’s collective interest if we are to avoid repeating mistakes and help future generations to prevent epidemics.”

Jeremy Farrar

Director (2013-2023)